The pathogenesis of Parkinson's disease (PD) involves a complex interplay of several cellular mechanisms, with α-synuclein aggregation being a central feature. However, multiple other processes, including mitochondrial dysfunction, impaired protein clearance, and neuroinflammation, contribute to disease development and progression. The precise relationships among these pathways are still not fully understood, but each plays a significant role in the neurodegeneration that characterizes PD.
α-synuclein Misfolding and Aggregation
At the heart of Parkinson’s disease, pathogenesis is the abnormal aggregation of α-synuclein, a protein that is normally found in neurons. Native α-synuclein exists in an unfolded state, though it can form stable tetramers that resist aggregation under normal conditions. In PD, α-synuclein misfolds into β-sheet structures that are prone to form insoluble aggregates. These misfolded forms accumulate as filaments in Lewy bodies, a hallmark of PD pathology. Various post-translational modifications, such as phosphorylation and ubiquitination, may contribute to α-synuclein's misfolding. It is believed that the soluble oligomeric form of α-synuclein, rather than the mature fibrils, is the most neurotoxic. These oligomers can seed further aggregation and may contribute to the spread of PD pathology throughout the brain. The spread of these aggregates is thought to follow a prion-like mechanism, where misfolded proteins induce the misfolding of normal proteins in neighboring cells.
Mitochondrial Dysfunction
Mitochondrial dysfunction is another key element in the pathogenesis of Parkinson’s disease. Defects in mitochondrial complex-I, which is critical for energy production, have been consistently observed in postmortem studies of the substantia nigra (SN) in PD patients. This deficiency leads to impaired cellular energy production and increased oxidative stress, both of which are harmful to neurons. Evidence for mitochondrial dysfunction in PD also comes from the discovery of the neurotoxin MPTP, which selectively damages dopaminergic neurons by inhibiting complex-I. This led to the understanding that environmental toxins mimicking MPTP could contribute to PD. Moreover, genetic forms of PD have provided further links to mitochondrial dysfunction. Mutations in genes such as PINK1 and parkin impair the cellular process of mitophagy, which is responsible for clearing defective mitochondria. Dysfunctional mitochondria lead to an accumulation of oxidative damage and contribute to the death of dopaminergic neurons.
Impaired Protein Clearance Systems
Protein clearance systems, particularly the ubiquitin-proteasome system (UPS) and the autophagy-lysosome pathway play a significant role in Parkinson’s pathogenesis. The UPS is responsible for tagging and degrading abnormal proteins. In PD, there is substantial evidence of reduced UPS activity in dopaminergic neurons. Proteasome components, such as the 20S subunit, are found at lower levels in PD brains, leading to the accumulation of misfolded proteins like α-synuclein. Furthermore, genetic mutations in UPS-related genes, such as parkin and UCH-L1, which encode proteins involved in ubiquitination, have been linked to familial PD.
The autophagy-lysosome pathway is another essential mechanism for protein degradation, and its dysfunction also contributes to PD. Studies have shown that autophagic vacuoles accumulate in the neurons of PD patients, suggesting a failure in the autophagic process. Lysosomal proteins such as LAMP1 and LAMP2A, which are critical for lysosome function, are reduced in PD, leading to impaired degradation of α-synuclein. Mutations in genes associated with lysosomal function, such as GBA1 (which encodes glucocerebrosidase), further highlight the importance of this pathway in PD pathogenesis.
Neuroinflammation
Neuroinflammation, characterized by the activation of microglia and the infiltration of immune cells into the brain, is increasingly recognized as a contributor to Parkinson’s disease. In postmortem studies, elevated levels of pro-inflammatory cytokines and activated microglia have been observed in the substantia nigra of PD patients. This inflammation is not merely a secondary response to neuronal damage; it may actively contribute to neurodegeneration. Experimental models of PD, such as MPTP or 6-hydroxydopamine (6-OHDA)-treated rodents, have shown that inhibiting microglial activation can reduce dopaminergic neuron loss, suggesting that neuroinflammation exacerbates the disease process.
The role of α-synuclein in promoting neuroinflammation is also well-established. Misfolded α-synuclein can trigger microglial activation, which in turn releases pro-inflammatory mediators that may lead to further neuronal damage. Additionally, genetic studies have implicated immune system genes, such as those encoding the human leukocyte antigen (HLA) class II, in increasing PD risk, providing further evidence of the involvement of immune responses in disease pathogenesis.
